查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971319

腦膜炎雙球菌疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、年齡層、地區和競爭格局分類，2021-2031年

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate, Polysaccharide, Combination, Others), By Age Group (Infant, Children & Adult), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腦膜炎雙球菌疫苗市場預計將從 2025 年的 43.8 億美元成長到 2031 年的 61.8 億美元，複合年成長率為 5.91%。

這些生物製藥對於建立針對腦膜炎雙球菌的免疫力、預防腦膜炎和敗血症等嚴重侵襲性疾病至關重要。市場成長的主要驅動力是這些疫苗被納入國家免疫規劃，以及對前往流行地區（例如舉措和副朝）的旅客實施嚴格的監管要求。此外，政府支持的青少年補種疫苗計畫以及私部門對B群腦膜炎雙球菌疫苗的日益普及也促進了收入成長。

市場概覽
預測期 2027-2031
市場規模：2025年 43.8億美元
市場規模：2031年 61.8億美元
複合年成長率：2026-2031年 5.91%
成長最快的細分市場 複雜類型
最大的市場 北美洲

然而，由於疫苗研發成本高以及低收入地區配送所需的複雜低溫運輸物流等因素，疫苗市場面臨許多障礙。儘管這些經濟和物流障礙限制了疫苗的普及，但不斷上升的感染率凸顯了公共衛生問題的迫切性。例如，根據美國疾病管制與預防中心（CDC）的報告，2024年美國確診和估計的病菌感染疾病病例數將達到503例，這是自2013年以來的最高年度數字。儘管供應鏈的複雜性和定價挑戰阻礙了全球市場滲透，但這些數據表明，儘管供應鏈複雜且價格高昂，但仍迫切需要有效的疫苗。

市場促進因素

推動市場發展的因素之一是近期非洲和歐洲侵襲性腦膜炎雙球菌病菌感染激增，迫使各國政府加強監測並實施緊急免疫措施。這次疫情反彈對先前被認為已控制的地區造成了重大影響，因此需要即時採購疫苗以遏制疫情蔓延。根據英國衛生與安全局 (UKHSA) 2025 年 11 月發布的公告，2024-2025 年英格蘭確診的侵襲性病菌感染病例數從上年度的340 例增至 378 例。為因應這些流行病學變化，各國正在擴大免疫接種計畫並推動接觸者追蹤宣傳活動，隨著當局集中精力控制疫情蔓延，疫苗訂單也不斷增加。

同時，隨著先進的多價結合疫苗的問世，市場也不斷發展，只需一劑即可提供多種血清型的保護。這些創新簡化了大規模免疫接種的物流，尤其是在需要嚴格低溫運輸管理的高風險地區。 2025年4月，全球疫苗免疫聯盟（Gavi）迎來了一個重要的里程碑：奈及利亞獲得了超過100萬劑新型五價腦膜炎雙球菌結合疫苗（Men5CV），用於應對嚴重的疫情爆發。這種向綜合配方發展的趨勢正在提升主要生產商的財務表現。例如，葛蘭素史克（GSK）在2025年10月報告稱，其腦膜炎疫苗第三季銷售額達到5億英鎊，年增5%，這主要得益於強勁的國際需求。

市場挑戰

腦膜炎雙球菌疫苗的全球市場受到疫苗研發高成本和維持低溫運輸完整性的物流挑戰的嚴重限制。製造商在研發和生產過程中投入大量資金，導致疫苗價格往往超出發展中國家的醫療預算。運輸過程中嚴格的溫度控制要求進一步加劇了這種經濟差距，使得在缺乏可靠基礎設施的地區分發疫苗變得異常困難。因此，該市場難以覆蓋撒哈拉以南非洲的高需求地區，其商業性可行性主要局限於疾病發生率低的富裕地區。

由於無法以可負擔的價格建立穩定的供應鏈，市場被迫依賴被動的、由捐助者資助的緊急措施，而非永續的商業管道。近期的一些營運統計數據凸顯了這種被動應對方式的優勢。根據全球疫苗免疫聯盟（Gavi）統計，到2024年底，16個國家已動用了68次多價腦膜炎雙球菌疫苗緊急儲備，需要運送超過3,440萬劑疫苗來控制疫情。這凸顯了資金和物流方面的限制如何將市場活動局限於零星的緊急應變，阻礙了市場向更廣泛、更穩定的收入模式轉型。

市場趨勢

五價腦膜炎雙球菌疫苗（MenABCWY）的推廣正在改變市場格局。這種疫苗將針對五種血清型的保護整合到單一的免疫接種方案中，有效解決了青少年時期多劑次接種依從性下降的問題。這一趨勢在美國等已開發市場尤為顯著，領先的製藥公司正在獲得核准，將B型腦膜炎球菌成分與標準B型腦膜炎雙球菌（MenACWY）結合疫苗相結合。這項轉變的關鍵進展是美國食品藥物管理局（FDA）於2025年2月核准了PenMenV，這是一種適用於10至25歲族群的新型五點疫苗。葛蘭素史克（GSK）報告稱，這些組合產品最大限度地減少了所需的接種劑量，並有望提高B型腦膜炎雙球菌的疫苗接種率。由於複雜的接種通訊協定，B型腦膜炎雙球菌的接種率歷來都低於其他血清群。

同時，將B群腦膜炎雙球菌疫苗納入國家免疫規劃是一項重大的政策轉變，使這些產品從民營市場選擇轉變為政府強制必需品。歐洲衛生當局日益重視嬰幼兒的普遍疫苗接種，以預防侵襲性腦膜炎雙球菌病菌感染的嚴重後果，並透過公共採購確保市場規模。法國衛生署於2025年1月決定強制所有嬰兒接種B群腦膜炎雙球菌疫苗，並制定了3、5和12個月大的標準接種程序，這清楚地反映了這項政策進展。此類監管變化將要求生產商調整其供應鏈以適應國家競標，從而在確保穩定需求的同時，消除先前限制高風險兒童群體獲得疫苗的經濟障礙。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（結合型、多醣型、混合型、其他）
    • 依年齡層別（嬰兒、兒童、成人）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腦膜炎雙球菌疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球腦膜炎雙球菌疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sanofi SA
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Pfizer, Inc.
  • Walwax Biotechnology Co., Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24314

The Global Meningococcal Vaccines Market is projected to expand from USD 4.38 Billion in 2025 to USD 6.18 Billion by 2031, reflecting a compound annual growth rate of 5.91%. These biological preparations are crucial for establishing immunity against Neisseria meningitidis bacteria, thereby preventing severe invasive conditions like meningitis and septicemia. The market's growth is primarily fuelled by the integration of these vaccines into national immunization programs and strict regulatory requirements for travelers visiting endemic areas, such as pilgrims performing Hajj and Umrah. Furthermore, revenue growth is bolstered by government-supported catch-up initiatives for adolescents and the increasing commercial adoption of Serogroup B vaccines within the private sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.38 Billion
Market Size 2031USD 6.18 Billion
CAGR 2026-20315.91%
Fastest Growing SegmentCombination
Largest MarketNorth America

However, the market faces significant obstacles due to the substantial costs associated with vaccine development and the intricate cold-chain logistics necessary for distribution in low-income regions. These economic and logistical barriers restrict accessibility, even as rising infection rates underscore a critical public health need. For example, the Centers for Disease Control and Prevention reported 503 confirmed and probable cases of meningococcal disease in the United States in 2024, the highest annual figure since 2013. This data emphasizes the urgent demand for effective vaccines, even as supply chain complexities and pricing challenges hinder broader global market penetration.

Market Driver

A major catalyst for the market is the recent increase in invasive meningococcal disease outbreaks across Africa and Europe, which is urging governments to strengthen surveillance and implement emergency vaccination measures. This resurgence is notably affecting areas where the disease was previously thought to be managed, necessitating immediate vaccine procurement to halt transmission. According to the UK Health Security Agency in November 2025, confirmed invasive meningococcal disease cases in England increased to 378 during the 2024-25 period, up from 340 the prior year. Such epidemiological changes are prompting the expansion of national immunization schedules and catch-up campaigns, resulting in higher vaccine order volumes as authorities focus on containment.

Concurrently, the market is evolving through the distribution of advanced multivalent conjugate vaccines, which provide protection against multiple serogroups in a single dose. These innovations simplify the logistics of mass immunization, especially in high-risk areas with challenging cold-chain requirements. A significant milestone was noted by Gavi, the Vaccine Alliance, in April 2025, when Nigeria received over one million doses of the new pentavalent meningococcal conjugate vaccine (Men5CV) to fight a severe outbreak. This trend toward comprehensive formulations is improving the financial results of leading manufacturers; for instance, GSK reported in October 2025 that its meningitis vaccine sales reached £0.5 billion in the third quarter, a 5% rise driven by robust international demand.

Market Challenge

The expansion of the Global Meningococcal Vaccines Market is heavily restricted by the high costs of vaccine development coupled with the logistical difficulties of maintaining cold-chain integrity. Manufacturers face substantial expenses during research and production, leading to pricing structures that often exceed the healthcare budgets of developing nations. This economic gap is worsened by the need for strict temperature controls during transport, making distribution impractical in areas without reliable infrastructure. As a result, the market struggles to reach high-demand populations in Sub-Saharan Africa, limiting commercial viability primarily to wealthier regions with lower disease incidence.

This failure to establish affordable, routine supply chains compels the market to depend on reactive, donor-funded emergency measures rather than sustainable commercial channels. The dominance of this reactive approach is highlighted by recent operational statistics. According to Gavi, the Vaccine Alliance, by the end of 2024, the emergency stockpile for multivalent meningococcal vaccines was utilized 68 times by 16 countries, requiring the shipment of over 34.4 million doses to manage outbreaks. This underscores how financial and logistical constraints effectively limit market activity to sporadic emergency responses, hindering the shift toward a broader and more stable revenue model.

Market Trends

The commercial landscape is being transformed by the shift toward Pentavalent MenABCWY combination vaccines, which consolidate protection against five serogroups into a single regimen to address low compliance with multi-injection schedules among adolescents. This trend is especially strong in developed markets such as the United States, where pharmaceutical leaders are achieving regulatory approvals for formulations combining standard MenACWY conjugates with Serogroup B components. A key development in this transition was reported by GSK in February 2025, when the US Food and Drug Administration (FDA) approved Penmenvy, a new pentavalent vaccine for individuals aged 10 to 25. By minimizing the number of required injections, these combination products are anticipated to boost coverage rates for Serogroup B, which has historically trailed other serogroups due to complex administration protocols.

At the same time, the integration of Serogroup B vaccines into national immunization schedules represents a significant policy shift, elevating these products from private-market options to government-mandated essentials. European health authorities are increasingly prioritizing universal infant coverage to prevent the severe consequences of invasive meningococcal disease, thereby securing market volume through public procurement. This policy evolution was illustrated in January 2025, when the Ministry of Health in France made vaccination against meningococcal serogroup B mandatory for all infants, establishing a standard schedule with doses at 3, 5, and 12 months. Such regulatory changes force manufacturers to align their supply chains with national tenders, ensuring consistent demand while eliminating financial barriers that previously limited access for high-risk pediatric populations.

Key Market Players

  • Sanofi S.A.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Pfizer, Inc.
  • Walwax Biotechnology Co., Ltd

Report Scope

In this report, the Global Meningococcal Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Meningococcal Vaccines Market, By Type

  • Conjugate
  • Polysaccharide
  • Combination
  • Others

Meningococcal Vaccines Market, By Age Group

  • Infant
  • Children & Adult

Meningococcal Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Meningococcal Vaccines Market.

Available Customizations:

Global Meningococcal Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Meningococcal Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Conjugate, Polysaccharide, Combination, Others)
    • 5.2.2. By Age Group (Infant, Children & Adult)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Meningococcal Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Age Group
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Meningococcal Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Age Group
    • 6.3.2. Canada Meningococcal Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Age Group
    • 6.3.3. Mexico Meningococcal Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Age Group

7. Europe Meningococcal Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Age Group
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Meningococcal Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Age Group
    • 7.3.2. France Meningococcal Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Age Group
    • 7.3.3. United Kingdom Meningococcal Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Age Group
    • 7.3.4. Italy Meningococcal Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Age Group
    • 7.3.5. Spain Meningococcal Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Age Group

8. Asia Pacific Meningococcal Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Age Group
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Meningococcal Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Age Group
    • 8.3.2. India Meningococcal Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Age Group
    • 8.3.3. Japan Meningococcal Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Age Group
    • 8.3.4. South Korea Meningococcal Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Age Group
    • 8.3.5. Australia Meningococcal Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Age Group

9. Middle East & Africa Meningococcal Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Age Group
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Meningococcal Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Age Group
    • 9.3.2. UAE Meningococcal Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Age Group
    • 9.3.3. South Africa Meningococcal Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Age Group

10. South America Meningococcal Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Age Group
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Meningococcal Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Age Group
    • 10.3.2. Colombia Meningococcal Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Age Group
    • 10.3.3. Argentina Meningococcal Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Age Group

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Meningococcal Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck & Co., Inc.
  • 15.3. GlaxoSmithKline plc
  • 15.4. Serum Institute of India Pvt. Ltd.
  • 15.5. Pfizer, Inc.
  • 15.6. Walwax Biotechnology Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer